
CAS 10079-35-3
:Fórmula:C22H34N4O4S
InChI:InChI=1S/C22H34N4O4S/c27-21(24-18-7-3-1-4-8-18)23-16-15-17-11-13-20(14-12-17)31(29,30)26-22(28)25-19-9-5-2-6-10-19/h11-14,18-19H,1-10,15-16H2,(H2,23,24,27)(H2,25,26,28)
Chave InChI:FYNBBKUBRFUWKU-UHFFFAOYSA-N
SMILES:C1CCC(CC1)NC(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3
Filtrar por
Percentagem de pureza
0
100
|
0
|
50
|
90
|
95
|
100
Foram encontrados 9 produtos.
- Preços em ordem crescente
- Preços em ordem decrescente
- Menor grau de pureza
- Maior grau de pureza
- Estimativa de entrega mais rápida
1-cyclohexyl-3-(4-{2-[(cyclohexylcarbamoyl)amino]ethyl}benzenesulfonyl)urea
CAS:1-cyclohexyl-3-(4-{2-[(cyclohexylcarbamoyl)amino]ethyl}benzenesulfonyl)ureaFórmula:C22H34N4O4SPureza:95%Peso molecular:450.59Glibenclamide (Glyburide) EP Impurity C (Glipizide EP Impurity I)
CAS:Fórmula:C22H34N4O4SCor e Forma:White To Off-White SolidPeso molecular:450.60Glipizide impurity 12
CAS:Glipizide impurity 12 is an impurity of Glipizide.Fórmula:C22H34N4O4SPeso molecular:450.60Glibenclamide EP Impurity C (Glipizide EP Impurity I)
CAS:Produto ControladoFórmula:C22H34N4O4SCor e Forma:NeatPeso molecular:450.59N-[4-(beta-Cyclohexylureidoethyl)benzensulfonyl] N'-Cyclohexylurea
CAS:Impurity Glipizide EP Impurity I
Applications N-[4-(β-Cyclohexylureidoethyl)benzensulfonyl] N’-Cyclohexylurea (Glipizide EP Impurity I) is a Glipizide (G410225) impurity.Fórmula:C22H34N4O4SCor e Forma:NeatPeso molecular:450.59N-(Cyclohexylcarbamoyl)-4-(2-((cyclohexylcarbamoyl)amino)ethyl)benzenesulfonamide
CAS:N-(Cyclohexylcarbamoyl)-4-(2-((cyclohexylcarbamoyl)amino)ethyl)benzenesulfonamide is a drug product that is an analytical standard. It is metabolized in the body to 4-aminobenzenesulfonamide and cyclohexylurea. This product has been shown to have antibacterial activity against Mycobacterium tuberculosis, Mycobacterium avium, and other bacteria. It also has analgesic properties, which may be due to its ability to inhibit prostaglandin synthesis.Fórmula:C22H34N4O4SPureza:Min. 95%Peso molecular:450.6 g/mol








